Skip to main content

Table 1 Descriptive data for 950 patients with early rheumatoid arthritis at time of inclusion and at 5-year follow-up a

From: Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study

Variables

YORA (N= 475)

LORA (N= 75)

P-value

Age at onset, yr

<58

≥58

 

Female, n (%)

357/475 (75.2)

292/475 (61.5)

 

Disease duration (mo)

6.90 (3.42)

6.45 (3.20)

<0.05

RF+, n (%)

354/466 (75.9)

349/468 (75.6)

NS

ANA+, n (%)

91/377 (24.2)

69/352 (19.6)

NS

ACPA+ n (%)

313/429 (72.9)

267/411 (64.9)

<0.05

PTPN22 T variant, n (%)

155/405 (38.3)

106/381 (27.8)

<0.01

HLA-SE, shared epitope, n (%)

237/405 (58.5)

219/381 (57.5)

NS

ESR at T0, mm/h (n = 948)

26.0 (21.5)

34.3 (24.2)

<0,001

CRP at T0 mg/L (n = 888)

18.3 (23.7)

23.0 (24.6)

<0.01

DAS28 at T0, (n = 788)

4.5 (1.5)

4.8 (1.4)

<0.01

AUC DAS28 (6 mo)b

24.5 (7.2)

25.9 (7.0)

<0.01

AUC DAS28 (12 mo)b

44.8 (13.4)

47.7 (13.2)

<0.01

AUC DAS28 (24 mo)b

84.2 (26.8)

89.0 (23.3)

<0.05

HAQ at T0, (n = 796)

0.81 (0.6)

0.92 (0.6)

<0.01

Tender joints at T0 (n = 811)

6.3 (5.6)

6.5 (5.7)

NS

Swollen joints at T0, (n = 812)

6.8 (5.2)

7.3 (5.2)

NS

VAS pain at T0 (mm), (n = 800)

43.5 (25.5)

43.4 (25.9)

NS

VAS global at T0 (mm) (n = 800)

44.0 (25.8)

45.0 (25.5)

NS

Smoker (ever) T0, n (%)

287/443 (64.8)

300/447 (67.1)

NS

Ex-RA ≤ T5, n (%)c,d

13/344 (3.8)

14/313 (4.5)

NS

Nodules ≤ T5, n (%)c

60/312 (19.2)

38/275 (13.8)

0.079

DMARDs within 3 mo after T0, n (%)c,e

325/346 (93.9)

267/311 (85.9)

<0.001

DMARDs (ever) ≤T5, n (%)c

344/348 (98.9)

299/310 (96.5)

<0.05

Methotrexate (ever) ≤T5, n (%)c

313/346 (90.5)

253/311 (81.4)

<0.001

Biologics (ever) ≤T5, n (%)c

84/342 (24.6)

23/310 (7.4)

<0.001

NSAID T0, n (%)

317/455 (69.7)

297/466 (63.7)

0.056

NSAID ever ≤T5, n (%)c

307/340 (90.3)

233/307 (75.9)

<0.001

COX-2-inhibitors at T0, n (%)

48/459 (10.5)

64/468 (13.7)

NS

COX-2-inhibitors (ever) ≤T5, n (%)c

95/342 (27.8)

83/309 (26.8)

NS

Corticosteroids T0 to T5 (mo)c

20.3 (23.8)

24.7 (23.8)

<0.01

Corticosteroids (ever) ≤T5 (%)c

230/346 (66.5)

233/309 (75.4)

<0.01

Hypertension at T0, n (%)

56/471 (11.9)

199/474 (41.9)

<0.001

DM at T0, n (%)

22/464 (4.7)

54/470 (11.5)

<0.001

CVD before T0, n (%)f

17/471 (3.6)

93/474 (19.6)

<0.001

CVD related comorbidity at T0, n (%)g

86/475 (18.1)

238/475 (50.1)

<0.001

Larsen score 0 (mo) (n = 437)

5.3 (5.8)

8.5 (6.2)

<0.001

Larsen score 24 (mo) (n = 381)

9.5 (9.1)

12.5 (8.2)

<0.001

Erosions 0 mo, n (%)

85/212 (40.1)

105/192 (54.7)

<0.01

Erosions 24 mo, n (%)

107/173 (61.8)

119/158 (75.3)

<0.01

Δ Larsen score 0 to 24 mo ≥3, n (%)

103/207 ( 49.8)

97/173 ( 56.1)

0.131

  1. aACPA, Anticyclic citrullinated peptide/protein; ANA, Antinuclear antibody; AUC, Area under the curve; CVD, Cardiovascular disease; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; DM, Diabetes mellitus; DMARD, Disease-modifying antirheumatic drug; ESR, Erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; LORA, Late-onset rheumatoid arthritis; NS, Not significant; NSAID, Nonsteroidal anti-inflammatory drug; PTPN22, Protein tyrosine phosphatase nonreceptor type 22; RA, Rheumatoid arthritis; RF, Rheumatoid factor; SD: Standard deviation; SE, Shared epitope; VAS, Visual Analogue Scale; YORA, Young-onset rheumatoid arthritis. bAUC for DAS28 at 6 months after inclusion, YORA/LORA (n = 367/343); AUC for DAS28 at 12 months after inclusion, YORA/LORA (n = 308/281); AUC for DAS28 at 24 months after inclusion, YORA/LORA (n = 231/199). cPatients followed for 5 years (n = 665). dCriteria used for severe extraarticular manifestations: pericarditis, pleuritis, interstitial lung disease, Felty’s syndrome, neuropathy, scleritis/episcleritis, glomerulonephritis, major cutaneous vasculitis and vasculitis involving other organs [42]. eDMARD treatment started within 3 months from baseline (T0). fCVD comorbidities as previously described in detail [41]. gCVD-related comorbidity at time of inclusion (T0): CVD, hypertension or DM present before T0.